CB
Chetan Bipinchandra Shah
About Chetan Bipinchandra Shah
Chetan Bipinchandra Shah has 2 years in corporate governance. Holds Director and Whole-Time Director roles. Currently with 3 companies, including Ratnatris Pharmaceuticals Private Limited and Senores Pharmaceuticals Limited. Formerly with 1 company. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Ratnatris Pharmaceuticals Private Limited
U24230GJ2005PTC047394
|
Director | 14 May 2025 | 2005 | Active |
Senores Pharmaceuticals Limited
L24290GJ2017PLC100263
|
Whole-Time Director | 10 Nov 2023 | 2017 | Active |
Apnar Pharma Private Limited
U73100GJ2014PTC081520
|
Additional Director | 16 Jan 2026 | 2014 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Ratnagene Lifescience Private Limited
U24231GJ2021PTC125613
|
Director | 05 Feb 2024 | 2021 | Amalgamated |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Chetan Bipinchandra Shah
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chetan Bipinchandra Shah
Chetan Bipinchandra Shah has 2 years in corporate governance. Holds Director and Whole-Time Director roles. Currently with 3 companies, including Ratnatris Pharmaceuticals Private Limited and Senores Pharmaceuticals Limited. Formerly with 1 company. Engaged in General Business. Contributes to corporate operations.
Chetan Bipinchandra Shah is associated with 3 companies as Director and Whole-Time Director.
Chetan Bipinchandra Shah has expertise in General Business.
Chetan Bipinchandra Shah has 2 years in corporate governance.